<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>同写意 | wechat-feeds</title><link>http://MzA4MzgzMDM5Mg.favicon.privacyhide.com/favicon.ico</link><description>一个以新药创制为核心，汇集国内一流研发精英的大型交流与价值分享平台。“同筑技术人生路，写意中国新药魂”是同写意的初衷与愿景。秉承汇集“一线、一流”，讲求“实用、实在、时效”的原则。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 15 Feb 2021 13:27:36 +0800</pubDate><image><url>http://MzA4MzgzMDM5Mg.favicon.privacyhide.com/favicon.ico</url><title>同写意 | wechat-feeds</title><link>http://MzA4MzgzMDM5Mg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>写意讨论丨百奥泰Her—2 ADC项目终止，创新药临床开发11个问</title><link>https://mp.weixin.qq.com/s/1SnFwCJImRm0HAcHsHFrJw</link><description></description><content:encoded><![CDATA[写意讨论丨百奥泰Her—2 ADC项目终止，创新药临床开发11个问]]></content:encoded><pubDate>Mon, 15 Feb 2021 11:39:14 +0800</pubDate></item><item><title>发挥抗体偶联药物的抗癌潜力，要注意这几点</title><link>https://mp.weixin.qq.com/s/WvKi-lXfGmY48GJbG1i8hg</link><description></description><content:encoded><![CDATA[发挥抗体偶联药物的抗癌潜力，要注意这几点]]></content:encoded><pubDate>Mon, 15 Feb 2021 11:39:14 +0800</pubDate></item><item><title>国内药企的her2-ADC，谁能成功干翻T-DM1？</title><link>https://mp.weixin.qq.com/s/V9Hk41QI7dsyllpLTnmM5Q</link><description></description><content:encoded><![CDATA[国内药企的her2-ADC，谁能成功干翻T-DM1？]]></content:encoded><pubDate>Mon, 15 Feb 2021 11:39:14 +0800</pubDate></item><item><title>大写意：登山则情满于山，观海则意溢于海</title><link>https://mp.weixin.qq.com/s/Rw5Qc8QmN-I14eVe6raDrQ</link><description></description><content:encoded><![CDATA[大写意：登山则情满于山，观海则意溢于海]]></content:encoded><pubDate>Sun, 14 Feb 2021 18:27:35 +0800</pubDate></item><item><title>蒋华良：久违的年味</title><link>https://mp.weixin.qq.com/s/xtB0dk3TghtQCIMTBAt4tg</link><description></description><content:encoded><![CDATA[蒋华良：久违的年味]]></content:encoded><pubDate>Sun, 14 Feb 2021 18:27:35 +0800</pubDate></item><item><title>百亿HER2单抗市场，曲妥珠单抗生物类似药是否能迎来春天？</title><link>https://mp.weixin.qq.com/s/7EOMFC2rc4Wa_8sr89nZAA</link><description></description><content:encoded><![CDATA[百亿HER2单抗市场，曲妥珠单抗生物类似药是否能迎来春天？]]></content:encoded><pubDate>Sun, 14 Feb 2021 18:27:35 +0800</pubDate></item><item><title>生物制剂管线全解析！</title><link>https://mp.weixin.qq.com/s/BzKPNxWXHf61YhiKrQ2Xzg</link><description></description><content:encoded><![CDATA[生物制剂管线全解析！]]></content:encoded><pubDate>Sun, 14 Feb 2021 18:27:35 +0800</pubDate></item><item><title>冠科美博：攻克肿瘤，“黄金三角”版图再添“新式武器”</title><link>https://mp.weixin.qq.com/s/9oxCPr9pGJuAkRtwr4uRlw</link><description></description><content:encoded><![CDATA[冠科美博：攻克肿瘤，“黄金三角”版图再添“新式武器”]]></content:encoded><pubDate>Sat, 13 Feb 2021 14:23:26 +0800</pubDate></item><item><title>我是砖家我怕谁？</title><link>https://mp.weixin.qq.com/s/cVDDZPZMrQJrp6bC2y0aBw</link><description></description><content:encoded><![CDATA[我是砖家我怕谁？]]></content:encoded><pubDate>Sat, 13 Feb 2021 14:23:26 +0800</pubDate></item><item><title>First do no harm：FDA批准首款缓解化疗骨髓抑制药物</title><link>https://mp.weixin.qq.com/s/ir9FZ7Rsa374MD-HAcYIxw</link><description></description><content:encoded><![CDATA[First do no harm：FDA批准首款缓解化疗骨髓抑制药物]]></content:encoded><pubDate>Sat, 13 Feb 2021 14:23:26 +0800</pubDate></item><item><title>回归初心 一同写意</title><link>https://mp.weixin.qq.com/s/WZRLjr8GZWcCC6NPKG4c7g</link><description></description><content:encoded><![CDATA[回归初心 一同写意]]></content:encoded><pubDate>Fri, 12 Feb 2021 11:36:05 +0800</pubDate></item><item><title>FDA批准新型降脂药Evkeeza</title><link>https://mp.weixin.qq.com/s/DHjxer8CSpoieP6M9R1o5w</link><description></description><content:encoded><![CDATA[FDA批准新型降脂药Evkeeza]]></content:encoded><pubDate>Fri, 12 Feb 2021 11:36:05 +0800</pubDate></item><item><title>大年三十，敬您一杯酒</title><link>https://mp.weixin.qq.com/s/xHKDkWMQwuqlLSecTdlQPQ</link><description></description><content:encoded><![CDATA[大年三十，敬您一杯酒]]></content:encoded><pubDate>Thu, 11 Feb 2021 16:02:47 +0800</pubDate></item><item><title>同写意祝大家牛年吉祥，牛气冲天！</title><link>https://mp.weixin.qq.com/s/8wAmyDRg5LUGmpAC_7i-UQ</link><description></description><content:encoded><![CDATA[同写意祝大家牛年吉祥，牛气冲天！]]></content:encoded><pubDate>Thu, 11 Feb 2021 16:02:47 +0800</pubDate></item><item><title>同写意新药临床研发俱乐部理事们来给大家拜年啦！</title><link>https://mp.weixin.qq.com/s/vwjAW-a09BrhUn4htvTAaQ</link><description></description><content:encoded><![CDATA[同写意新药临床研发俱乐部理事们来给大家拜年啦！]]></content:encoded><pubDate>Thu, 11 Feb 2021 16:02:47 +0800</pubDate></item><item><title>写意会员 | 恒诺康创始人张健存博士来给大家拜年啦！</title><link>https://mp.weixin.qq.com/s/NPnPSSdil1Sl1jy7nGUxIw</link><description></description><content:encoded><![CDATA[写意会员 | 恒诺康创始人张健存博士来给大家拜年啦！]]></content:encoded><pubDate>Thu, 11 Feb 2021 16:02:47 +0800</pubDate></item><item><title>写意会员丨亚盛医药董事长杨大俊博士来给大家拜年啦！</title><link>https://mp.weixin.qq.com/s/qZea3YVrgwiCFJkLf7KKGA</link><description></description><content:encoded><![CDATA[写意会员丨亚盛医药董事长杨大俊博士来给大家拜年啦！]]></content:encoded><pubDate>Thu, 11 Feb 2021 16:02:47 +0800</pubDate></item><item><title>写意发布丨Etesevimab（JS016）与bamlanivimab双抗体疗法获FDA紧急使用授权用于治疗COVID-19</title><link>https://mp.weixin.qq.com/s/vyUjWFayo3fFJTrf_JeAIg</link><description></description><content:encoded><![CDATA[写意发布丨Etesevimab（JS016）与bamlanivimab双抗体疗法获FDA紧急使用授权用于治疗COVID-19]]></content:encoded><pubDate>Wed, 10 Feb 2021 20:09:24 +0800</pubDate></item><item><title>关注杜丨礼来与君实的联合抗体疗法获得FDA紧急使用授权</title><link>https://mp.weixin.qq.com/s/CKHqL5EqISqI2j44KtHonw</link><description></description><content:encoded><![CDATA[关注杜丨礼来与君实的联合抗体疗法获得FDA紧急使用授权]]></content:encoded><pubDate>Wed, 10 Feb 2021 20:09:24 +0800</pubDate></item><item><title>巴西Samel医院和科学家对开拓药业普克鲁胺治疗重症新冠患者临床试验表示乐观</title><link>https://mp.weixin.qq.com/s/irBQTxqSIfW3A4VAk8kpIQ</link><description></description><content:encoded><![CDATA[巴西Samel医院和科学家对开拓药业普克鲁胺治疗重症新冠患者临床试验表示乐观]]></content:encoded><pubDate>Wed, 10 Feb 2021 20:09:24 +0800</pubDate></item></channel></rss>